Ketamine hydrochloride is a Small Molecule owned by Seelos Therapeutics, and is involved in 5 clinical trials, of which 1 was completed, 3 are ongoing, and 1 is planned.

Ketamine acts as AMPA receptor agonist and NMDA receptor antagonist. AMPA receptors are responsible for the bulk of fast excitatory synaptic transmission throughout the CNS. The drug candidate intensifies the action of the AMPA type glutamate receptors in the brain, which may in turn influence cognitive functions such as thinking, attention, and memory. It also modulates excitatory neurotransmission mediated by NMDA receptors by binding to the strychnine-insensitive glycine recognition site of the NMDA receptor complex.The drug candidate enhances excitatory communication, thereby partially or completely restoring the brains excitatory communication.

The revenue for Ketamine hydrochloride is expected to reach a total of $244m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ketamine hydrochloride NPV Report.

Ketamine hydrochloride is currently owned by Seelos Therapeutics.

Ketamine hydrochloride Overview

Ereska (intranasal ketamine, PMI-150, SLS-002) is under development for the treatment of suicidality in post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). The drug candidate is administered through intranasal route. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA) and glutamate ionotropic receptor NMDA type subunit.

It was also under development for the treatment of postoperative pain and pain in cancer patients.

Seelos Therapeutics Overview

Seelos Therapeutics (Seelos) is a clinical-stage biopharmaceutical company that focuses on developing novel technologies and therapeutics for the treatment of central nervous system (CNS) and other rare disorders. Its lead programs include SLS-002, SLS-005, and pipeline products include SLS-004, SLS-008, SLS-007, SLS-010 and SLS-012. Seelos pipeline products find application in treating various multiple CNS disorders including parkinson’s disease, sanflippo syndrome, suicidality post-traumatic stress disorders, major depressive disorders and other diseases such as atopic dermatitis, asthma, and pediatric esophagitis. It operates along with its subsidiaries. Seelos is headquartered in New York, the US.

The operating loss of the company was US$63.9 million in FY2021, compared to an operating loss of US$18.8 million in FY2020. The net loss of the company was US$66.1 million in FY2021, compared to a net loss of US$19.1 million in FY2020.

Quick View – Ketamine hydrochloride

Report Segments
  • Innovator
Drug Name
  • Ketamine hydrochloride
Administration Pathway
  • Nasal
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.